Topiramate in chronic daily headache due to migraine;Topiramato en cefalea crónica diaria por migraña

Revista de Neurologia

Volumn 45, Issue 8, 2007, Pages 456-459

  Gracia Naya, Manuel ^a   Latorre Jimenez A M ^d   Rios Gomez C ^e   Santos Lasaosa, S ^b   Mauri, J A ^b   Sanchez Valiente S ^c   Lopez E ^b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c HOSPITAL ROYO VILLANOVA   (Spain)

^d HOSPITAL SAN JORGE   (Spain)

^e HOSPITAL DE BARBASTRO   (Spain)

Author keywords

Chronic daily headache; Chronic migraine; Headache; Migraine; Migraine treatment; Topiramate

Indexed keywords

TOPIRAMATE;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CONFUSION; DIARRHEA; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; PARESTHESIA; TINGLING SENSATION; TREATMENT RESPONSE; VOMITING;

EID: 37349000274     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4508.2007265     Document Type: Article

References (40)

1. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near daily headaches: field trial of revised HIS criteria. Neurology 1996; 47: 871-5.
2. Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol 2000; 13: 277-83.
3. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998; 38: 497-506.
4. Castillo J, Muñoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190-6.
5. Gracia-Naya M, Latorre A, García de Pablo MS. Valoración de los pacientes con migraña enviados a una unidad de cefaleas. Neurología 2001; 16: 446-7.
6. Headache Classification Committee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004; 24 (Suppl): S1-160.
7. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache 1987; 27: 102-6.
8. Mathew NT. Chronic refractory headache. Neurology 1993; 43 (Suppl): S26-33.
9. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al, Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-6.
10. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646-57.
11. Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004; 62: 788-90.
12. Monzón JM, Láinez JM. Quality of life in migraine and chronic daily headache patients. Cephalalgia 1998; 18: 638-43.
13. Laml C, Buzath A, Yazdi K, Sandor PS. Ergot and triptan overuse in Austria -an evaluation of clinical data and cost. Cephalalgia 2002; 22: 807-11.
14. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3: 475-83.
15. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache. The effect of a 2 month drug-free period. Neurology 2006; 66: 1894-8.
16. Colás R, Muñoz P, Temprano R, Gómez C, Pascual J. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 2004; 62: 1338-42.
17. Chakravarty A. Chronic daily headache in children and adolescents: a clinic based study from India. Cephalalgia 2005; 25: 795-800.
18. Ramadan NM. Current trends in migraine prophylaxis. Headache 2007; 47 (Suppl): S52-7.
19. Mathew NT. The prophylactic treatment of chronic daily headache: CME. Headache 2006; 46: 1552-64.
20. Volcy-Gómez M. Cefalea crónica diaria: II. Tratamiento. Rev Neurol 2005; 40: 180-7.
21. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003; 23: 820-4.
22. Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005; 28: 277-9.
23. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew NT, et al, on behalf of the Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-80.
24. Spira PJ, Beran RG, Australian Gabapentin Chronic Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 2003; 61: 1753-9.
25. Saper JR, Lake AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study Headache 2002; 42: 470-82.
26. Saper JR, Silberstein SD, Lake AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994; 34: 497-502.
27. Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline vs amitriptyline combined with fluoxetine in the preventive treatment of transformed migraine: A double-blind study. Headache 2002; 42: 510-4.
28. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, for the Botox CDH Study Group. Botulinum toxin type A (Botox) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45: 293-307.
29. Silberstein SD, Stark SR, Lucas SM, Christie SM, De Gryse RE, Turkel CC. Botulinum toxin type A (Botox) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80: 1126-37.
30. Headache Classification Committee of International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8: 1-96.
31. Ferrari A, Leone S, Vergoni AV, Bertolini A, Sances G, Cocía CP, et al. Similarities and differences between chronic migraine and episodic migraine. Headache 2007; 47: 65-72.
32. Limmroth V, Biondi D, PfeilJ, Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache 2007; 47: 13-21.
33. Rothrock JF, Parada VA, Drinkard R, Zweifler RM, Key KF. Predictors of a negative response to topiramate therapy in patients with chronic migraine. Headache 2005; 45: 932-5.
34. Gracia-Naya M, Latorre A. Efectividad de topiramato en la profilaxis de la migraña. Estudio observacional en una serie consecutiva de casos. Neurología 2005; 20: 225-31.
35. Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, et al. Guidelines for controlled trials of drugs in migraine. Cephalalgia 2000; 20: 765-86.
36. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al, for the MIGR-002 Study Group. Topiramate for migraine prevention. A randomized controlled trial. JAMA 2004; 291: 965-73.
37. Silberstein SD, Neto W, Schmitt J, Jacobs D, for the MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490-5.
38. Rapoport A, Mauskop A, Diener HC, Schwalen S, Pfeil J. Long-term migraine prevention with topiramate: open label extension of pivotal trials. Headache 2006; 46: 1151-60.
39. Stenlof K, Rossner S, Vercruysse F, Kumar A, Fitchet M, Sjostrom L. Topiramate in the treatment of obese subjects with drug-naïve type 2 diabetes. Diabetes Obes Metab 2007; 9: 306-68.
40. Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled-release in the treatment of obese, type 2 diabetic patients. Diabetes Care 2007; 30: 1480-6.